Phibro Animal Health (NASDAQ:PAHC) Raised to "Strong-Buy" at StockNews.com

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was upgraded by research analysts at StockNews.com from a "buy" rating to a "strong-buy" rating in a report issued on Wednesday.

A number of other research firms also recently issued reports on PAHC. Morgan Stanley lifted their price objective on shares of Phibro Animal Health from $20.00 to $25.00 and gave the company an "equal weight" rating in a report on Tuesday. Bank of America lifted their price target on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an "underperform" rating in a research note on Friday, August 30th. Barclays increased their price objective on shares of Phibro Animal Health from $13.00 to $20.00 and gave the stock an "underweight" rating in a research note on Tuesday, November 12th. Finally, JPMorgan Chase & Co. began coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They issued a "neutral" rating and a $22.00 target price on the stock. Two analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $20.50.

Phibro Animal Health Stock Down 4.8 %

PAHC traded down $1.07 during trading on Wednesday, reaching $21.27. The company had a trading volume of 162,460 shares, compared to its average volume of 157,644. The company has a market cap of $861.50 million, a P/E ratio of 49.47, a PEG ratio of 0.58 and a beta of 0.51. Phibro Animal Health has a 12 month low of $10.03 and a 12 month high of $25.98. The company has a debt-to-equity ratio of 1.81, a current ratio of 3.23 and a quick ratio of 1.69. The business's fifty day moving average price is $23.63 and its 200 day moving average price is $20.66.

Hedge Funds Weigh In On Phibro Animal Health

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PAHC. Sofinnova Investments Inc. bought a new position in Phibro Animal Health in the second quarter valued at approximately $3,975,000. American Century Companies Inc. boosted its holdings in shares of Phibro Animal Health by 119.6% in the 2nd quarter. American Century Companies Inc. now owns 347,191 shares of the company's stock valued at $5,822,000 after purchasing an additional 189,068 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Phibro Animal Health by 116.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 192,255 shares of the company's stock valued at $4,330,000 after purchasing an additional 103,491 shares during the last quarter. Dana Investment Advisors Inc. raised its holdings in shares of Phibro Animal Health by 17.2% during the 2nd quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company's stock worth $8,619,000 after buying an additional 75,546 shares in the last quarter. Finally, Algert Global LLC lifted its position in shares of Phibro Animal Health by 521.1% during the 3rd quarter. Algert Global LLC now owns 71,335 shares of the company's stock worth $1,606,000 after buying an additional 59,850 shares during the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.